文献速递瓣膜外科主动脉外科

主动脉瓣多次再手术:结局及对未来瓣中瓣策略的启示

Multiple reoperations on the aortic valve: outcomes and implications for future potential valve-in-valve strategy.
PubMed 文献 · Eur J Cardiothorac Surg · 2018-01-01

研究纳入2007年1月至2016年12月单中心316例连续接受主动脉瓣开放再置换手术的患者,按既往主动脉瓣干预次数分为三组。院内总死亡率为7.3%,组间比较P=0.233。术前NYHA III/IV级、再次开胸时损伤、心内膜炎及同期二尖瓣置换为院内死亡的独立危险因素。全队列8年生存率为79.0±3.0%,结构性瓣膜衰败再置换后为88.4±3.2%。

要点

  • 院内总死亡率为7.3%,首次、第二次及第三次以上再干预分别为7.2%、4.76%和18.2%(P=0.233)。
  • 术前NYHA III/IV级(OR 15.9,P=0.011)和再次开胸时损伤(OR 16.9,P=0.015)为院内死亡的独立危险因素。
  • 心内膜炎(OR 3.7,P=0.038)和同期二尖瓣置换(OR 5.6,P=0.006)亦为院内死亡的独立危险因素。

核心结论

  • 多次主动脉瓣再手术的早期术后死亡风险可接受,尤其是因结构性瓣膜衰败行孤立瓣膜置换者。

研究设计与样本

  • 单中心研究,纳入2007年1月至2016年12月316例连续接受主动脉瓣开放再置换手术的患者;首次再干预263例(第1组),第二次42例(第2组),第三次或以上11例(第3组)。

主要发现

  • 患者中男性230例、女性86例,中位年龄58岁(Q1-Q3:46-70岁)。
  • 再干预最常见原因为生物瓣结构性瓣膜衰败(n=136,44%)、心内膜炎(n=57,18%)和人工瓣膜裂开(n=41,13%)。
  • 院内总死亡率为7.3%:第1组7.2%,第2组4.76%,第3组18.2%(P=0.233);按原因从结构性瓣膜衰败的3.7%至心内膜炎的14.0%不等。
  • 术前NYHA III/IV级(OR 15.9,P=0.011)、再次开胸时损伤(OR 16.9,P=0.015)、心内膜炎(OR 3.7,P=0.038)和同期二尖瓣置换(OR 5.6,P=0.006)为院内死亡的独立危险因素。
  • 全队列8年生存率为79.0±3.0%,结构性瓣膜衰败再置换后为88.4±3.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Surgical mortality and long-term outcomes are important considerations when determining strategies for multiple reoperations on the aortic valve (AV). With the rise of percutaneous valve-in-valve, we sought to evaluate the current outcomes of conventional surgery for AV reoperation, focusing first on the effect of the number of previous AV interventions with a subsequent analysis of the risk factors for adverse outcomes. METHODS: From January 2007 to December 2016, 316 consecutive patients underwent an open redo operation (replacement) on their AV at a single centre. It was the first AV reintervention in 263 patients (Group 1), second in 42 patients (Group 2) and third or more in 11 patients (Group 3). RESULTS: There were 230 men and 86 women, with a median age of 58 (Q1-Q3: 46-70) years. Structural valve deterioration (SVD) of the bioprosthesis (n = 136, 44%), endocarditis (n = 57, 18%) and prosthetic valve dehiscence (n = 41, 13%) were the most common reasons for reintervention. Overall, in-hospital mortality was 7.3%: 7.2% in Group 1, 4.76% in Group 2 and 18.2% in Group 3 (P = 0.233) and ranged from 3.7% for SVD to 14.0% when endocarditis was the reason for reintervention. Higher preoperative New York Heart Association (NYHA) class (III/IV) [odds ratio (OR) 15.9, P = 0.011], injury during re-entry (OR 16.9, P = 0.015), endocarditis (OR 3.7, P = 0.038) and concomitant mitral valve replacement (OR 5.6, P = 0.006) were independent risk factors for in-hospital mortality. Survival at 8 years was 79.0 ± 3.0% for the entire cohort and 88.4 ± 3.2% for re-replacement after SVD. CONCLUSIONS: Multiple AV reoperations carry an acceptable risk of early postoperative mortality, particularly for isolated valve replacements of SVD.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Joshi Y, Achouh P, Menasché P, et al. Multiple reoperations on the aortic valve: outcomes and implications for future potential valve-in-valve strategy. Eur J Cardiothorac Surg. 2018. PMID: 29293911. doi:10.1093/ejcts/ezx469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。